Cytek Biosciences, Inc. (CTKB) Earnings Call Transcript
November 4, 2026
Earnings Call Speaker Segments
Thanks, operator. With me on today's call from Cytek are Wenbin Jiang, our CEO, and Bill McCombe, our CFO. Cytek Biosciences issued its financial results for the third quarter, which ended September 30, 2026, earlier today. Should you not have received that news release, or if you would like to be added to the company's distribution list, you can email investors@cytekbio.com. The news release is also posted in the investor relations section of Cytek's website, at investors.cytekbio.com. Please be aware that during today's call we will reference a slide presentation, which has been posted to the investor section of our corporate website. Just a quick note before we start—on slide two, you'll see that some of what we say today counts as forward-looking statements under federal securities law. That covers things like Cytek's plans for the business, its strategies, the opportunities it sees, and its financial projections. These remarks reflect what the company currently expects, and by their nature they carry substantial risks and uncertainties, so actual results or events could end up differing materially from what these statements anticipate. You can find more detail on those risks and uncertainties in the Forward-Looking Statements section of our slide presentation, in the press release Cytek put out today, and in Cytek's SEC filings. During this call, we'll also go over some financial metrics that aren't computed under generally accepted accounting principles. You can find more details on how we use these non-GAAP measures—including reconciliations to the closest comparable GAAP figures—in our slide deck and in today's press release. Although the company feels these non-GAAP metrics offer helpful information to investors, presenting them isn't meant to be viewed on their own or as a replacement for the financial data we report under GAAP; we'll also give a short update on our ongoing patent litigation during this call. If you want fuller details on this matter, including the counterclaims we have filed, you should look at our earlier press release and our SEC filings, among them the Form 10-Q we are submitting today. Cytek undertakes no obligation to revise any forward-looking statements unless the law requires it, whether due to fresh information, later events, or shifts in its expectations. The content of this call is time-sensitive and holds true solely as of the live webcast on November 4, 2026; having said that, I'll hand things over to Wenbin.
Thanks, Mark. Hello, everyone, and we appreciate your interest in Cytek. To start today's call, I'll cover our third-quarter performance and go over some business highlights, after which Bill will take over for a detailed review of our financial results and our full-year outlook. If you'll turn to slides three and four. The third quarter brought another solid result, with revenue of $53.2 million, up 2% year-over-year. Growth in the U.S. stood out in the third quarter, powered by sustained strong demand for our high-end Full Spectrum Profiling instruments, with Aurora Evo leading the way, along with double-digit growth in our service business and our robust gross margin performance. The U.S. drove third-quarter growth, with revenue rising 12% year-over-year to $30.4 million, extending the strong momentum from the first half on instrument sales to academic and government customers plus continued service growth. EMEA third-quarter revenue came in at $12.5 million, up 1% year-over-year — an encouraging signal following a difficult first half, reflecting better instrument sales to academic and government customers. Total APAC revenue, China included, reached $8.3 million, a 5% increase sequentially versus Q2, though down 25% against a strong Q3 last year. Moving to slide five. Success at the high end stood out in the third quarter, where our technology leadership keeps shining. Aurora Evo is winning customer preference because it enables large-panel runs and delivers consistent, reproducible data at greater throughput. The automation configurations launched last quarter added further value for customers, and the API for automated plate handling systems integrates smoothly into the high-volume workflows of our pharma and CRO customers. Placements of Aurora and Aurora Evo together rose 23% year-over-year, while Evo placements almost doubled year-over-year, which shows robust demand for our next-generation platform. Thanks to these strong placements, revenue from high-end Full Spectrum Profiling instruments increased 11%. In the broader business, we added 140 instruments in total during the quarter, lifting our total install base to 4,073 units. Borealis is our latest platform, launched just last quarter, and it's drawing significant customer interest across academia and biopharma alike. During Q3, we expanded our early access program to twice its previous size. To recap, Borealis is a Full Spectrum Profiling cytometer equipped with seven lasers; it has already shown 60-color performance, and there's an obvious route to surpass that as new dyes and panels emerge. Once we reach full commercial launch, it will also feature integrated imaging. Alongside our new proprietary cFluor reagent, Borealis makes single-tube 60-color panels possible, and it additionally supports nanoparticle analysis as well as higher sampling rates. Participants in the early access program are enthusiastic about the ways these features could improve insight and speed up discovery in their laboratories. During the fourth quarter, we'll keep growing that early access program, and we intend a wider commercial release in fiscal year 2027. Moving to slide six. During Q3, we launched an analysis tool named Cytek Cloud — which is the industry's first end-to-end platform that unites the entire flow cytometry workflow, from panel design through data analysis, in one system. Researchers will enjoy a seamless experience covering experiment planning through data analysis, with less switching among systems or rebuilding of workflows. Cloud analysis is available in the U.S. We introduced Cytek Cloud Premium, a fresh subscription level that bundles cloud-based data analysis with online data storage. This rollout represents a major step toward our goal of making Cytek Cloud a full digital ecosystem that supports flow cytometry workflows from start to finish. As of the end of the third quarter, Cytek Cloud users totaled nearly 30,000, which is more than 20% higher than at the start of the year. Our recurring revenue continued to grow during the third quarter. Service and reagent revenue together reached $19.1 million in Q3 2026, representing 36% of Cytek's revenue on a trailing 12-month basis, versus 33% for the 12 months ended September 30, 2025. Looking ahead, we anticipate that an increasing portion of overall revenue will come from recurring sources. During the quarter, our patent litigation also produced notable developments. On August 21st, we announced that a jury in the U.S. District Court for the District of Delaware decided in our favor on three of the four asserted claims, determining both no infringement and invalidity as to each of those three; regarding the fourth claim, the jury concluded there was no literal infringement yet did find infringement under the doctrine of equivalents, and we do not believe the legal standards applicable to infringement under the doctrine of equivalents have been met. We have submitted post-trial motions asking the court to set aside the verdict on this basis and additional grounds, and we intend to exhaust all legal options available to us. Nothing about the jury's decision requires us to alter what we offer or how we operate, and we can still sell and ship our products as before. It's worth noting that the patent in question is a U.S. patent, so it covers only instrument sales occurring within the United States or involving instruments brought into the country. Finally, I want to provide an update regarding the new business unit structure that we rolled out earlier this year. Following a thorough evaluation, we have chosen to delay putting these business units into effect until the start of 2027. We determined that the danger of moving to our new organizational structure partway through the year was too great in the near term. We still believe that structure is the finest method for supporting our long-term growth, yet we acknowledge how essential it is to perform well through the rest of 2026. We keep directing resources and expanding our team in order to grow our instruments and reagents aimed at clinical and solution-focused work. Looking at the broader picture, we felt good about how the business performed overall. In Q3, a notable highlight was the continued strength of our high-end Aurora Evo and Borealis analyzers, together with double-digit growth in our service business, and Bill will cover that shortly. Our operations team executed very well, giving us our strongest third-quarter gross margin since 2023. With revenue performance matching what we had anticipated, we are reaffirming the midpoint of our full-year 2026 revenue guidance. I'll now hand the call to Bill, who will share more on our Q3 financials and the outlook for the full year.
Thanks, Wenbin. Let's turn to slide seven. Revenue for the third quarter came in at $53.2 million, up 2% compared with Q3 2025. The highlight this quarter was strong customer demand for our high-end analyzers, as revenue in the Aurora Evo and Borealis category climbed more than 30%. That largely drove U.S. total revenue growth of 12% and instrument growth of 9%. In EMEA, total revenue returned to modest year-over-year growth of 1%, with instrument growth of 3%, after two quarters of declines. APAC, China included, rose 5% sequentially from Q2, although it was down 25% against a strong Q3 2025. Academic and government customers delivered particularly strong revenue, climbing 38% year-over-year to $24.5 million, with every region contributing. In the U.S., the largest region for that end market, instrument revenue increased by more than 60%. Revenue from biopharma distributors and CROs dropped about 17% year-over-year to $28.7 million, compared with a strong Q3 last year. Product revenue, which consists of instruments and reagents, came to $37.2 million, a 3% year-over-year decline, as gains in our high-end instruments were offset by lower imaging and mid to low-end instrument sales. Service revenue grew 13% year-over-year, supported by expansion of our installed base and ongoing active use of our systems. Let's move to slide eight. Turning to gross margin, Wenbin mentioned it, and we posted a really strong outcome: GAAP gross profit came in at $31.2 million for Q3, with gross margin at 59% against 53% in Q3 2025 — that's close to 600 basis points better, driven by improvements in both product and service gross margin. Product gross margin climbed 770 basis points to 61%, up from 53% in last year's Q3. The main driver there was reduced overhead costs after we finished shifting manufacturing capacity from Seattle to Singapore, plus lower material costs and lower tariffs. Service gross margin came in at 53%, compared with 51% in Q3 2025. That improvement reflects service revenue growth of 13%, which outpaced the 8% rise in service cost of sales. We are now realizing the full benefit of shifting manufacturing earlier this year from our Seattle site to our Singapore facility. This shift forms part of our region-for-region manufacturing strategy, which provides lower-cost manufacturing capacity, greater supply flexibility, and helps mitigate tariff-related cost pressures. Total operating expenses reached $39.6 million in Q3, an 8% increase versus Q3 2025. Research and development expenses were $9.4 million, up 4%, while sales and marketing expenses came to $11.9 million, up 2%. G&A expense came in at $18.4 million, which is $2.2 million higher, or 14%, versus Q3 2025. The driver was a $3 million rise in legal costs tied to our patent litigation — more specifically, the trial that took place in August. Now that the costliest trial phase of this case is behind us, we'd anticipate legal expenses dropping by $3 million-$4 million in Q4 relative to Q3. Operating loss for the third quarter was $8.4 million, versus a $9.2 million loss in the same quarter a year earlier. On a GAAP basis, net loss was $6.1 million, compared with a $5.5 million loss in Q3 2025. That larger GAAP net loss reflects a $1.5 million reduction in tax benefit, partly offset by a $0.8 million gain in operating loss. Adjusted EBITDA — which strips out stock-based compensation along with foreign exchange gains and losses — was $0.7 million in Q3 2026, down from $2.5 million in Q3 2025. The main reasons for the drop were reduced investment income and elevated operating expenses. We expect adjusted EBITDA to pick up substantially in Q4, since revenue should rise in line with our usual seasonal trend. As of September 30, 2026, cash, cash equivalents, restricted cash, and marketable securities came to $256 million, down from $262 million on June 30, 2026. A strong balance sheet keeps giving us the financial flexibility to put money into our global growth priorities. Moving to slide nine. We're holding the midpoint of our full year 2026 revenue guidance and tightening the range to $208 million-$211 million; that assumes current currency exchange rates stay unchanged. It captures results so far this year along with the growth outlook across our markets. For the fourth quarter, revenue should be substantially above Q3, in keeping with our typical seasonality, fueled by the usual year-end buying patterns from customers and ongoing expansion in our service business. Across full year 2026, we still expect adjusted EBITDA near break-even, which reflects an anticipated robust Q4 outcome powered by the seasonal revenue lift as well as a significant reduction in litigation spending. With that, I'll hand it back to Wenbin.
Thanks, Bill. Before we wrap up, I'd like to express appreciation to everyone at Cytek for the ongoing commitment and the work they do for our stakeholders. We had a solid third quarter, and we're expecting to end the year strongly. These results show how strong our technology leadership is within the flow cytometry industry. As we look forward, we feel we're in a good position going into next year. We keep gaining share, since our new product portfolio reinforces our technology leadership position across biopharma and academic research markets. We also expect better performance with clinical customers, fueled by our new organizational structure along with the advantages of our Sysmex collaboration in Europe. Last, we anticipate delivering improving profitability as we keep driving leverage on increased volume and expect reduced G&A spend tied to lower litigation expenses. Thank you all for being on today's call. We'll now open the line for questions.
Hi, Harrison here, filling in for Mason. Appreciate you taking our questions. To begin, could you walk us through what the 2026 guidance range looks like? Should we be expecting service revenue to keep expanding at roughly that low double-digit pace in Q4, with product revenue covering the rest?
Yes. Service revenue for us has risen pretty steadily, so my expectation is that it carries on at rates comparable to what we've seen in recent quarters, and product revenue would cover the remainder; that's correct.
Understood. Now, when we look forward to 2027, I believe you earlier said the growth rate from the second half of 2026 would be a reasonable starting point for the following year. Is that way of thinking still valid as of today, and what's your view on growth next year across the various regions?
Right, I don't believe we've said anything specific about providing guidance on 2027 growth, so I won't weigh in on that framework of yours. What I can tell you is that we will keep at it; we'll provide more detailed guidance at the time we report Q4 revenue in late February or early March. That said, we'd anticipate growing faster than the market in 2027; we keep putting investment into our high-end product portfolio. As you're aware, we're going to launch the Borealis analyzer with full imaging capability. Its launch is planned for 2027. We're putting considerable resources behind expanding our low-to-mid-range instruments as well as our reagent portfolio. So we'll hold our leadership position at the high end, and we'll invest to grow the remaining areas of our business; we'd anticipate profitability improving, and beyond that I really can't offer more specific guidance. Still, on the strength of those investments and on the strength of what we've delivered so far, we'd anticipate growing faster than the market and faster than our peers.
Hey, guys. We appreciate your continued taking of market share next year, and we plan to outgrow the market. Do you still feel the markets may be flat, or do you think we have returned to growth here across end markets?
I think market growth has been better, really going back to the fourth quarter of last year and the first three quarters of this year. We have certainly done better than the early part of 2025. The market has been better. Some of the headwinds that occurred back then have abated. I think we feel that the market environment is generally positive.
Alright, thank you. So regarding the Cytek Cloud user base, the expansion there is quite striking. I'm just curious whether, inside the company, you see that as perhaps more of a protective barrier for your instruments as these tools get used more widely across workflows? Or is it something where, I know you began perhaps monetizing it somewhat in the past, but do you feel there's still plenty of upside to capture, and maybe that could add to service revenues?
The goal behind Cytek Cloud isn't really to extract profit from the platform on its own, correct? It's a means of helping our users take advantage of our complete solutions, including our instrument reagents and panel design, data analysis, all of it together, so that customers remain with what we offer.
All right, appreciate the questions, folks.
Hello, Skye here, filling in for Dave. Thanks for taking my questions. Perhaps to start, could you expand a little on biopharma? In the past you've seen growth from large pharma and biotech customers. I realize you mentioned the difficult comp this quarter, but has that momentum eased at all, and what does that imply for CROs and the smaller customers? And at the end of the day, how much of demand now reflects ongoing fleet deployments as opposed to individual instrument purchases?
Well, let me note that biopharma is up 3% year to date. Look, it has generally been uneven. We had some strong quarters toward the latter part of last year. Another thing that affects our reported numbers is that a disproportionate, much larger portion of total sales in Asia-Pac and China flow through distributors, which we include in the Biopharma, CRO, and Distributor category. As I believe we mentioned, conditions in the APAC and China markets during the third quarter were considerably softer, mainly because of macroeconomic factors in those markets. So that has somewhat muted the growth of what we report as the Biopharma, CRO, Distributor category. I think that's important to keep in mind. But we believe the biopharma sector, especially in the U.S., has money on hand for a year-end budget flush. We believe that the Aurora Evo, given its high throughput and automation capabilities, is a great product for that market. We remain broadly quite optimistic about that market segment.
That's quite useful, thank you. And one last thing — back in September, for a handful of the products you brought up, I believe you said you were selling all you could produce, and that orders tended to be placed and delivered inside the same quarter. Which areas are still limited on supply? Do lead times, ordering habits, or cancellations of some kind give you clearer insight into demand right now? Thanks.
Apart from modest volumes, we typically take orders and ship them. Almost everything we book gets shipped during a quarter. At the time of those remarks on the Q2 call, Borealis and the Aurora Evo with the enhanced automation capability were what we had in mind; we keep raising our output rate for those kinds of systems. So we see them as significant contributors down the road and as products enjoying quite strong customer demand. Supply constraints aren't really a major, aren't a large concern for us.
All right, thank you; that’s where we’ll wrap up the call. We appreciate all of you being with us, and if any follow-up questions come up, please don’t hesitate to contact us. Goodbye.
Ladies and gentlemen, you may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytek Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Cytek Biosciences, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.